MedTrace Logo

BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine

NCT03193346 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-07-14

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.

Conditions

  • Migraine Disorders

Interventions

BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.

DRUG

placebo (sodium chloride 0.9 mg)

Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Arlene Lum · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-03
Primary Completion
2021-03-25
Completion
2021-03-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193346 on ClinicalTrials.gov